Addition of SIRT to chemotherapy first-line treatment of metastatic CRC did not improve overall PFS or ORR, but substantially reduced the risk of disease progression in the liver.
Highest baseline vitamin D levels associated with OS and PFS improvement regardless of chemotherapy backbone and biologic assignment.
The largest cohort ever to examine the effects of aspirin as secondary prevention reveals that aspirin independently reduces the risk of both CRC-specific mortality and all-cause mortality.
Median overall survival was 11 months, with a median duration of response of 40 weeks with pembrolizumab in PD-L1–positive gastric cancer.
This slideset covers the final and subgroup results of the INTEGRATE phase II trial of regorafenib in refractory advanced gastroesophageal cancer as presented at the 2015 ASCO meeting.
In this pilot study, mFOLFIRINOX and chemoradiation were shown to be tolerable and allowed most patients to go on to resection.
In this CME-certified downloadable slideset, Thomas H. Cartwright, MD, reviews key studies on the management of GI cancers. Review the slide notes for Dr. Cartwright’s commentary.
Results of the first study utilizing tumor genetics to guide use of immunotherapy suggest that genomic instability may be more important than histology in conferring response to anti–PD-1 therapy.